A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

This Phase II trial is testing a drug called revumenib (a menin inhibitor) for patients with relapsed or refractory acute leukemia that has certain genetic changes involving HOX gene activation. It is open to a broader range of genetic subtypes than typical trials. **You may be eligible if...** - You are 12 or older and weigh at least 40 kg - You have acute leukemia (myeloid, lymphoid, or mixed lineage) that has come back or stopped responding to treatment - Your leukemia has a specific genetic alteration associated with HOX gene upregulation (such as KMT2A-PTD, NPM1-MLF1, NUP98 rearrangements, SET-NUP214, RUNX1-EVI1, or others listed in the protocol) - Your heart pumping function (ejection fraction) is above 40% - Your white blood cell count is below 25,000/uL at enrollment **You may NOT be eligible if...** - Your leukemia does not have a qualifying HOX-related genetic alteration - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.